Passive and Active Drug Targeting: Role of Nanocarriers in Rational Design of Anticancer Formulations

Abstract

Background: Cancer is the major public health problem in developing countries. The treatment of cancer requires a multimodal approach and chemotherapy is one of them. Chemotherapeutic drug is administered to cancer patients in the form of a formulation which is prepared by mixing an active ingredient (drug) with the excipient. The role of excipient in a formulation is to regulate the release, bio-distribution, and selectivity of drug within the body. Methods: In this context, selectivity of an anticancer formulation is achieved through two mechanisms like passive and active targeting. The passive targeting of a formulation is generally through enhanced permeation retention (EPR) effect which is dictated by physical properties of the carrier such as shape and size. On the contrary, active targeting means surface functionalization of excipient with target-specific ligands and/or receptors to increase its selectivity. Results: Over the past several decades, remarkable progress has been made in the development and application of an engineered excipient or carrier to treat cancer more effectively. Especially nanoparticulate systems composed of metal/liposomes/polymeric material/proteins have received significant attention in the rational design of anticancer drug formulations; for example, therapeutic agents have been integrated with nanoparticles of optimal sizes, shapes and surface properties to improve their solubility, circulation half-life, and bio-distribution. In this review article, recent literature is included to discuss the role of physicochemical properties of excipients in achieving tumour targeting through passive and active approaches. Conclusion: The selection of an excipient/carrier and targeting ligand plays a very important role in rational design and development of anticancer drug formulations.

Biodegradable Polymeric Nanoparticles for Drug Delivery to Solid Tumors

“…An overview of the two principal targets (the surfaces of cancer cells and endothelial tumor cells) is provided in supplementary material. A full discussion of this topic is beyond the scope of this review; however, several excellent review articles have been recently published ( Mukherjee et al, 2013 ; Bazak et al, 2014 ; Zhong et al, 2014 ; Choudhury et al, 2019 ; Das et al, 2019 ; Molavipordanjani and Hosseinimehr, 2019 ; Raj et al, 2019 ).…”

Mechanisms for Tuning Engineered Nanomaterials to Enhance Radiation Therapy of Cancer

“…Active targeting of nanomaterials to tumors, beyond the intrinsic EPR effect, has been discussed above [18,19] and is the focus of other reviews. [378] These and other authors review [11,43,[379][380][381] and discuss biological barriers in targeted NP delivery to tumors such as half-life of blood circulation, or opsonization, and opportunities, e.g., engineering of tumorassociated macrophages to act as a reservoir of nanotherapeutics from which the drug payload is gradually released. From the translational perspective, there is nothing particular in targeting nanomaterials for X-PDT, except perhaps if additional subcellular organelle targeting is required.…”

Recent Progress in the Development of Multifunctional Nanoplatform for Precise Tumor Phototherapy

“…Generally, targeting manners are mainly divided into two categories: passive targeting and active targeting. [23] The efficiency of passive targeting usually depends on the physicochemical properties of the nanocarriers and the pathological properties of the tumor. [24] For example, the size of the nanocarriers is critical in promoting the delivery and accumulation of PA at the tumor site.…”